Advertisement

Chilblain Lupus Erythematosus

  • Min Ae Lee-Kirsch
  • Martin AringerEmail author
  • Annegret Kuhn
Chapter

Abstract

Chilblain lupus is a typical, albeit rare, form of chronic cutaneous lupus erythematosus. With its name derived from similarities to chilblains (perniones), these painful, bluish-red acral manifestations usually do not pose major diagnostic difficulties, with differential diagnoses including true perniones, lupus pernio (sarcoidosis), and ischemia. However, recent findings, linking familial chilblain lupus to TREX1, and thus the innate immune system, have had significant impact on our understanding of the disease. Therefore, this chapter will not only review the clinical side, but also our current understanding of the pathogenic events preceding disease.

Keywords

Systemic Lupus Erythematosus Cutaneous Lupus Erythematosus Nucleic Acid Metabolism Chilblain Lupus Cell Cycle Checkpoint Activation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

We thank P. Wissel, J. Bückmann, and Professor T. A. Luger, University Muenster, Germany, for providing the clinical figures.

References

  1. 1.
    Kuhn A, et al. Clinical manifestations of cutaneous lupus erythematosus. In: Kuhn A, Lehmann P, Ruzicka T, editors. Cutaneous lupus erythematosus. Heidelberg: Springer 2004. pp. 59–92Google Scholar
  2. 2.
    Lee-Kirsch MA, et al. Familial chilblain lupus, a monogenic form of cutaneous lupus erythematosus, maps to chromosome 3p. Am J Hum Genet. 2006;79:731–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Lee-Kirsch MA, et al. A mutation in TREX1 that impairs susceptibility to granzyme A-mediated cell death underlies familial chilblain lupus. J Mol Med. 2007;85:531–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Rice G, et al. Heterozygous mutations in TREX1 cause familial chilblain lupus and dominant aicardi-goutières syndrome. Am J Hum Genet. 2007;80:811–5.PubMedCrossRefGoogle Scholar
  5. 5.
    Franceschini F, et al. Chilblain lupus erythematosus is associated with antibodies to SSA/Ro. Lupus. 1999;8:215–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Millard LG, et al. Chilblain lupus erythematosus (Hutchinson). A clinical and laboratory study of 17 patients. Br J Dermatol. 1978;98:497–506.PubMedCrossRefGoogle Scholar
  7. 7.
    Gunther C, et al. Familial chilblain lupus–a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1. Dermatology. 2009;219:162–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Rustin MH, et al. The treatment of chilblains with nifedipine: the results of a pilot study, a double-blind placebo-controlled randomized study and a long-term open trial. Br J Dermatol. 1989;120:267–75.PubMedCrossRefGoogle Scholar
  9. 9.
    Goette DK. Chilblains (perniosis). J Am Acad Dermatol. 1990;23:257–62.PubMedCrossRefGoogle Scholar
  10. 10.
    Kuhn A, et al. Clinical manifestations in cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2007;5:1124–37.PubMedCrossRefGoogle Scholar
  11. 11.
    Viguier M, et al. Clinical and histopathologic features and immunologic variables in patients with severe chilblains. A study of the relationship to lupus erythematosus. Medicine (Baltimore). 2001;80:180–8.CrossRefGoogle Scholar
  12. 12.
    Lee-Kirsch MA, et al. Mutations in the gene encoding the 3′-5′ DNA exonuclease TREX1 are associated with systemic lupus erythematosus. Nat Genet. 2007;39:1065–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Lee-Kirsch MA. Nucleic acid metabolism and systemic autoimmunity revisited. Arthritis Rheum. 2010;62:1208–12.PubMedCrossRefGoogle Scholar
  14. 14.
    Crow YJ, et al. Aicardi-Goutières syndrome displays genetic heterogeneity with one locus (AGS1) on chromosome 3p21. Am J Hum Genet. 2000;67:213–21.PubMedCrossRefGoogle Scholar
  15. 15.
    Ramantani G, et al. Expanding the phenotypic spectrum of lupus erythematosus in Aicardi-Goutières syndrome. Arthritis Rheum. 2010;62:1469–77.PubMedCrossRefGoogle Scholar
  16. 16.
    Stetson DB, et al. Trex1 prevents cell-intrinsic initiation of autoimmunity. Cell. 2008;134:587–98.PubMedCrossRefGoogle Scholar
  17. 17.
    Yang YG, et al. Trex1 exonuclease degrades ssDNA to prevent chronic checkpoint activation and autoimmune disease. Cell. 2007;131:873–86.PubMedCrossRefGoogle Scholar
  18. 18.
    Deininger PL, et al. Mobile elements and mammalian genome evolution. Curr Opin Genet Dev. 2003;13:651–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Yanai H, et al. Regulation of the cytosolic DNA-sensing system in innate immunity: a current view. Curr Opin Immunol. 2009;21:17–22.PubMedCrossRefGoogle Scholar
  20. 20.
    Ronnblom L, et al. Type I interferon and lupus. Curr Opin Rheumatol. 2009;21:471–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Richards A, et al. C-terminal truncations in human 3′-5′ DNA exonuclease TREX1 cause autosomal dominant retinal vasculopathy with cerebral leukodystrophy. Nat Genet. 2007;39:1068–70.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2014

Authors and Affiliations

  • Min Ae Lee-Kirsch
    • 1
  • Martin Aringer
    • 2
    Email author
  • Annegret Kuhn
    • 3
  1. 1.Children’s HospitalUniversity Medical Centre Carl Gustav Carus at the Technical University of DresdenDresdenGermany
  2. 2.Division of Rheumatology, Department of Medicine IIIUniversity Medical Centre Carl Gustav Carus at the Technical University of DresdenDresdenGermany
  3. 3.Department of DermatologyUniversity of MuensterMuensterGermany

Personalised recommendations